CMND Clearmind Medicine Inc., a clinical-stage Biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alco
CMND Clearmind Medicine Inc., a clinical-stage Biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder ("AUD"), addiction, and weight management, recently announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of AUD.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.